Clinical Data Viridian tumbles on positive data for key eye drug prospect BioPharma DiveThe data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.Clinical DataOphthalmologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) BioPharma Dive The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst. Clinical DataOphthalmologyRead full story Post navigation Previous: PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseNext: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
